NCT02337530 2024-03-21
Selumetinib in Patients Receiving Pemetrexed and Platinum-based Chemotherapy in Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous NSCLC
Canadian Cancer Trials Group
Phase 2 Completed
Canadian Cancer Trials Group
Canadian Cancer Trials Group